Replimune heads for the liver

Early indications at SITC last year that Replimune’s oncolytic virus approach was working in skin cancer sent the company’s stock up 50%, and further cuts of that data released today point to deepening responses. But the first look at a follow-on CTLA-4-armed project, RP2, combined with Opdivo, seemed to take the shine off the progress.